EU Clinical Trial 2017-000981-31

Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer.  Mar 11, 2019

Main objective of the trial: To determine if treatment with atezolizumab (arm B) is superior to a treatment without atezolizumab (arm A) in the improvement of 5-year Event-Free Survival (EFS). In case of superiority of arm B vs. arm A, a formal comparison of arm B1 vs arm A and arm B2 vs arm A will be tested for the 5-year EFS.

Parties

Sponsors
Countries
AT BE DE ES EU IT NL RO TW
Keywords
ATEZOLIZUMAB Atezolizumab PERTUZUMAB Perjeta Tecentriq 1,200 mg concentrate for solution for infusion

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.